• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Status report of lipid-lowering trials in diabetes.

作者信息

Betteridge D J, Colhoun H, Armitage J

机构信息

Department of Medicine, University College, London, UK.

出版信息

Curr Opin Lipidol. 2000 Dec;11(6):621-6. doi: 10.1097/00041433-200012000-00009.

DOI:10.1097/00041433-200012000-00009
PMID:11086336
Abstract

The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes. Diabetic dyslipidaemia is an important risk factor and is open to therapeutic intervention. However, as yet there are no primary or secondary coronary heart disease prevention trials of lipid-lowering therapy reported in diabetic populations. In this review, on-going clinical trials of lipid-lowering therapy in specific diabetic populations will be described.

摘要

相似文献

1
Status report of lipid-lowering trials in diabetes.
Curr Opin Lipidol. 2000 Dec;11(6):621-6. doi: 10.1097/00041433-200012000-00009.
2
Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.阿托伐他汀与微粒化非诺贝特治疗混合型高脂蛋白血症患者的疗效比较
Am J Cardiol. 2001 Jul 15;88(2):203. doi: 10.1016/s0002-9149(01)01660-5.
3
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.阿托伐他汀与非诺贝特对2型糖尿病合并混合型高脂血症患者脂蛋白谱、低密度脂蛋白亚组分分布及血液流变学参数的影响
Am J Cardiol. 2001 Jan 1;87(1):44-8. doi: 10.1016/s0002-9149(00)01270-4.
4
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.2型糖尿病患者降脂治疗期间低密度脂蛋白大小变化的预测因素
Metabolism. 2004 Nov;53(11):1516. doi: 10.1016/j.metabol.2004.07.005.
5
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp.
Diabetes Care. 2006 Nov;29(11):2561; author reply 2561-2. doi: 10.2337/dc06-1487.
6
Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.载脂蛋白CIII降低对12周微粒化非诺贝特在血脂异常患者中降低甘油三酯水平及低密度脂蛋白大小方面比阿托伐他汀疗法有更大疗效的作用。
Ann Med. 2003;35(6):442-8. doi: 10.1080/07853890310011969.
7
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.阿托伐他汀与微粒化非诺贝特单药及联合用药治疗2型糖尿病合并高脂血症的疗效观察
Diabetes Care. 2002 Jul;25(7):1198-202. doi: 10.2337/diacare.25.7.1198.
8
Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis.
Nephrol Dial Transplant. 2000 May;15(5):684-8. doi: 10.1093/ndt/15.5.684.
9
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.阿托伐他汀在2型糖尿病中对心血管疾病的一级预防：合作阿托伐他汀糖尿病研究（CARDS）：多中心随机安慰剂对照试验
Lancet. 2004;364(9435):685-96. doi: 10.1016/S0140-6736(04)16895-5.
10
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.降低2型糖尿病相关的冠心病：生活方式干预与血脂异常的治疗。
Diabetes Res Clin Pract. 2003 Jul;61 Suppl 1:S27-34. doi: 10.1016/s0168-8227(03)00125-6.

引用本文的文献

1
A rice bran oil diet improves lipid abnormalities and suppress hyperinsulinemic responses in rats with streptozotocin/nicotinamide-induced type 2 diabetes.米糠油饮食可改善链脲佐菌素/烟酰胺诱导的 2 型糖尿病大鼠的脂质异常和抑制高胰岛素血症反应。
J Clin Biochem Nutr. 2009 Jul;45(1):29-36. doi: 10.3164/jcbn.08-257. Epub 2009 Jun 30.